Maria Kinali

Maria Kinali

Auto-generated profile, based on publicly available information

Maria Kinali

Chelsea and Westminster NHS Foundation Trust

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2014 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
VSVincenzo Salpietro
Vincenzo Salpietro
RPRahul Phadke
Rahul Phadke
ASAnand Saggar
Anand Saggar
IHIain P. Hargreaves
Iain P. Hargreaves
RYRobert Yates
Robert Yates
MKMaria Kinali
Maria Kinali

20 June 2018 in Molecular Autism
Verified
Journal Article
Open access
PDF file
MBMatthew Benger
Matthew Benger
MKMaria Kinali
Maria Kinali
NMNicholas D. Mazarakis
Nicholas D. Mazarakis
Autism spectrum disorder (ASD) is characterised by the concomitant occurrence of impaired social interaction; restricted, perseverative and stereotypical behaviour; and abnormal communication skills. Recent epidemiological studies have reported a dramatic increase in the prevalence of ASD with as many as 1 in every 59 children being diagnosed with ASD. The fact that ASD appears to be principally genetically driven, and may be reversible postnatally, has raised the exciting possibility of using gene therapy as a disease-modifying treatment. Such therapies have already started to seriously impact on human disease and particularly monogenic disorders (e.g. metachromatic leukodystrophy, SMA type 1). In regard to ASD, technical advances in both our capacity to model the disorder in animals and also our ability to deliver genes to the central nervous system (CNS) have led to the first preclinical studies in monogenic ASD, involving both gene replacement and silencing. Furthermore, our increasing awareness and understanding of common dysregulated pathways in ASD have broadened gene therapy’s potential scope to include various polygenic ASDs. As this review highlights, despite a number of outstanding challenges, gene therapy has excellent potential to address cognitive dysfunction in ASD.

1 May 2016 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
EPEfterpi Pavlidou Pavlidou
Efterpi Pavlidou Pavlidou
VSVincenzo Salpietro
Vincenzo Salpietro
RPRahul Phadke
Rahul Phadke
IHIain P. Hargreaves
Iain P. Hargreaves
LBLeigh Batten
Leigh Batten
MKMaria Kinali
Maria Kinali

18 November 2015 in Journal of Genetics
Verified
Journal Article
Closed access
PDF file
DSDora Steel
Dora Steel
VSVincenzo Salpietro
Vincenzo Salpietro
RPRahul Phadke
Rahul Phadke
MPMatthew Pitt
Matthew Pitt
GGGiulia Gentile
Giulia Gentile
MKMaria Kinali
Maria Kinali

Verified
Journal Article
Open access
PDF file
EPEleni Paleologou
Eleni Paleologou
NINaila Ismayilova
Naila Ismayilova
MKMaria Kinali
Maria Kinali
Mitochondrial disorders are a clinically heterogeneous group of disorders that are caused by defects in the respiratory chain, the metabolic pathway of the adenosine tri-phosphate (ATP) production system. Epilepsy is a common and important feature of these disorders and its management can be challenging. Epileptic seizures in the context of mitochondrial disease are usually treated with conventional anti-epileptic medication, apart from valproic acid. However, in accordance with the treatment of intractable epilepsy where there are limited treatment options, the ketogenic diet (KD) has been considered as an alternative therapy. The use of the KD and its more palatable formulations has shown promising results. It is especially indicated and effective in the treatment of mitochondrial disorders due to complex I deficiency. Further research into the mechanism of action and the neuroprotective properties of the KD will allow more targeted therapeutic strategies and thus optimize the treatment of both epilepsy in the context of mitochondrial disorders but also in other neurodegenerative disorders.

25 January 2023 in Pediatric Neurology
Verified
Journal Article
Open access
SSSeth A. Stafki
Seth A. Stafki
JTJohnnie Turner
Johnnie Turner
HLHannah R. Littel
Hannah R. Littel
CBChristine C. Bruels
Christine C. Bruels
DTDon Truong
Don Truong
PKPeter B. Kang
Peter B. Kang
Cockayne syndrome (CS) is a DNA repair disorder primarily associated with pathogenic variants in ERCC6 and ERCC8. As in other Mendelian disorders, there are a number of genetically unsolved CS cases. We ascertained five individuals with monoallelic pathogenic variants in MORC2, previously associated with three dominantly inherited phenotypes: an axonal form of Charcot-Marie-Tooth disease type 2Z; a syndrome of developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy; and a rare form of spinal muscular atrophy. One of these individuals bore a strong phenotypic resemblance to CS. We then identified monoallelic pathogenic MORC2 variants in three of five genetically unsolved individuals with a clinical diagnosis of CS. In total, we identified eight individuals with MORC2-related disorder, four of whom had clinical features strongly suggestive of CS. Our findings indicate that some forms of MORC2-related disorder have phenotypic similarities to CS, including features of accelerated aging. Unlike classic DNA repair disorders, MORC2-related disorder does not appear to be associated with a defect in transcription-coupled nucleotide excision repair and follows a dominant pattern of inheritance with variants typically arising de novo. Such de novo pathogenic variants present particular challenges with regard to both initial gene discovery and diagnostic evaluations. MORC2 should be included in diagnostic genetic test panels targeting the evaluation of microcephaly and/or suspected DNA repair disorders. Future studies of MORC2 and its protein product, coupled with further phenotypic characterization, will help to optimize the diagnosis, understanding, and therapy of the associated disorders.